登录 | 注册    关注公众号  
微信公众号
搜索
 >  Cell>CD19 >CHEK-ATS056

HEK293/Human Anti-CD19 Stable Cell Line

For research use only.

描述(Description)

HEK293/Human Anti-CD19 Stable Cell Line

应用说明(Application)

Binding assay by FACS and cell based ELISA

生长特性(Growth Properties)

Adherent

筛选标记(Selection Marker)

Puromycin (5 μg/mL)

培养基(Culture Medium)

DMEM medium + 10% FBS

冻存液(Freeze Medium)

10% DMSO + 90% FBS

装量(Quantity)

1 vial contains at least 5x10^6 cells in 1 ml of 10% DMSO in FBS.

存储(Storage)

Frozen in liquid nitrogen.

支原体检测(Mycoplasma Testing)

Negative

无菌检测(Sterility Testing)

Negative

使用说明(Instructions for Use)

See data sheet for detailed culturing and assay protocol.

 

Receptor Assay

CD19 FACS

FACS assay shows that PE-Labeled Monoclonal Anti-FMC63 scFv Antibody, Mouse IgG1 can bind to HEK293/Human Anti-CD19 Stable Cell Line. HEK293/Human Anti-CD19 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Protocol

CD19 FACS

FACS assay shows that PE-Labeled Human CD19 (20-291), His Tag can bind to HEK293/Human Anti-CD19 Stable Cell Line. HEK293/Human Anti-CD19 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

Protocol

如有相关细胞池需求请联系我们

 

背景(Background)

Chimeric antigen receptors (CARs) comprise interact domains, of which target cancer cell expressed antigens and allow T cell to efficiently kill the cancer cell. FMC63 is an IgG2a mouse monoclonal antibody specific for CD19, which is a target for the immunotherapy of B lineage leukaemias and lymphomas. FMC63 scFv is the most commonly used ectodomain component of CD19-specific CARs. Our CAR-like cells apply the HEK293 cells for the expression of FMC63 which will be presented on the cell membrane. It mimics the real CAR-T cell reaction and it is used as positive control for Anti-CD19 scFv Antibody flow cytometry detection.

 

Permits & Restrictions

This cell line is provided for research use only. It is not intended for any animal or human therapeutic use, any human or animal consumption, or any diagnostic use. You are not allowed to share, distribute, sell, modify, sublicense, or otherwise make this cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. AcroBiosystems does not warrant the suitability of this cell line for any particular use, and does not accept any liability in connection with the handling or use of this cell line.

 

前沿进展

 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
CD19靶点信息
英文全称:B-lymphocyte antigen CD19
中文全称:B淋巴细胞抗原CD19
种类:Homo sapiens
上市药物数量:11详情
临床药物数量:291详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定